Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease
that affects more than a quarter of the global population and whose prevalence is increasing …

Abstract Sodium glucose cotransporter 2 (SGLT-2) inhibitors are the latest class of
antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted …

Background and aim Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has been verified
to improve Non-alcoholic fatty liver disease (NAFLD) in previous clinical practice. We mainly …

The prevalence and severity of metabolic dysfunction associated steatotic liver disease
(MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the …

Abstract Background and Aim This study aimed to clarify the efficacy and safety of oral
semaglutide treatment in patients with non‐alcoholic fatty liver disease (NAFLD) …

Purpose Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver
disease, affecting 30% of the global population. NAFLD prevalence is particularly high in …

MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to
today, the most effective treatment is weight loss. Weight loss interventions are moving from …

Background Dapagliflozin as a treatment option in patients with nonalcoholic fatty liver
disease (NAFLD) has received increasing attention, however, the efficacy and safety of …

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy during women's
reproductive age. PCOS is a heterogeneous disorder featuring specific cardiometabolic …